[go: up one dir, main page]

WO2000041505A3 - 4'heteroaryle diarylamines - Google Patents

4'heteroaryle diarylamines Download PDF

Info

Publication number
WO2000041505A3
WO2000041505A3 PCT/US1999/030491 US9930491W WO0041505A3 WO 2000041505 A3 WO2000041505 A3 WO 2000041505A3 US 9930491 W US9930491 W US 9930491W WO 0041505 A3 WO0041505 A3 WO 0041505A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid derivatives
anthranilic acid
compound
formula
treating
Prior art date
Application number
PCT/US1999/030491
Other languages
English (en)
Other versions
WO2000041505A2 (fr
Inventor
Haile Tecle
Stephen Douglas Barrett
Original Assignee
Warner Lambert Co
Haile Tecle
Stephen Douglas Barrett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Haile Tecle, Stephen Douglas Barrett filed Critical Warner Lambert Co
Priority to AU24834/00A priority Critical patent/AU2483400A/en
Priority to JP2000593128A priority patent/JP2002534446A/ja
Priority to EP99968160A priority patent/EP1150950A2/fr
Priority to BR9916857-0A priority patent/BR9916857A/pt
Priority to CA002349180A priority patent/CA2349180A1/fr
Publication of WO2000041505A2 publication Critical patent/WO2000041505A2/fr
Publication of WO2000041505A3 publication Critical patent/WO2000041505A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
    • C07C323/36—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)

Abstract

L'invention concerne des diarylamines pharmaceutiquement actifs, ainsi que leurs procédés de fabrication et d'utilisation.
PCT/US1999/030491 1999-01-13 1999-12-21 4'heteroaryle diarylamines WO2000041505A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU24834/00A AU2483400A (en) 1999-01-13 1999-12-21 4'heteroaryl diarylamines
JP2000593128A JP2002534446A (ja) 1999-01-13 1999-12-21 ４′ヘテロアリールジアリールアミン
EP99968160A EP1150950A2 (fr) 1999-01-13 1999-12-21 Derives d'acide anthranilique
BR9916857-0A BR9916857A (pt) 1999-01-13 1999-12-21 4 heteroaril diarilaminas
CA002349180A CA2349180A1 (fr) 1999-01-13 1999-12-21 4'heteroaryle diarylamines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11587699P 1999-01-13 1999-01-13
US12258399P 1999-03-02 1999-03-02
US60/122,583 1999-03-02
US60/115,876 1999-03-02

Publications (2)

Publication Number Publication Date
WO2000041505A2 WO2000041505A2 (fr) 2000-07-20
WO2000041505A3 true WO2000041505A3 (fr) 2000-10-19

Family

ID=26813668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030491 WO2000041505A2 (fr) 1999-01-13 1999-12-21 4'heteroaryle diarylamines

Country Status (6)

Country Link
EP (1) EP1150950A2 (fr)
JP (1) JP2002534446A (fr)
AU (1) AU2483400A (fr)
BR (1) BR9916857A (fr)
CA (1) CA2349180A1 (fr)
WO (1) WO2000041505A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271178B2 (en) 2003-09-03 2007-09-18 Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US9290468B2 (en) 2012-01-17 2016-03-22 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200205T2 (tr) * 1999-07-16 2002-06-21 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
CA2542210A1 (fr) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-fluoro-4-iodophenylamino)-benzamide
KR101099849B1 (ko) 2003-11-19 2011-12-28 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
KR101318012B1 (ko) 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
UA100007C2 (ru) 2005-05-18 2012-11-12 Астразенека Аб Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN109053523B (zh) * 2005-10-07 2022-03-25 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
JPWO2007132867A1 (ja) 2006-05-15 2009-09-24 杉本　芳一 癌の予防及び治療剤
CN101516891B (zh) 2006-07-06 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103288753A (zh) 2006-07-06 2013-09-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
NZ577047A (en) 2006-10-23 2011-02-25 Takeda Pharmaceutical Mapk/erk kinase inhibitors
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CA2692502C (fr) 2007-07-05 2016-03-01 Array Biopharma Inc. Cyclopentanes de pyrimidyle comme inhibiteurs de proteines kinases akt
KR101624361B1 (ko) 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2705452C (fr) 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Inhibiteurs de la mapk/erk kinase
RU2504542C2 (ru) 2008-01-09 2014-01-20 Эррэй Биофарма Инк. Гидроксилированные пиримидилциклопентаны в качестве ингибиторов протеинкиназы (акт)
ES2401685T3 (es) 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
EA018539B1 (ru) 2008-08-04 2013-08-30 Мерк Патент Гмбх Фениламино-изоникотинамидные соединения
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
EP2491016A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
EP2491015A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
EP2491014A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Dérivés d'halogénophénoxybenzamide substitués
EP2590957B1 (fr) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
JP2013542214A (ja) 2010-10-29 2013-11-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換フェノキシピリジン類
JP6147246B2 (ja) 2011-04-01 2017-06-14 ジェネンテック， インコーポレイテッド Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
MY179607A (en) 2011-04-01 2020-11-11 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
KR101599300B1 (ko) * 2012-03-14 2016-03-03 시노켐 코포레이션 치환 디페닐아민 화합물 및 항종양제로서의 용도
PE20191818A1 (es) 2012-10-12 2019-12-27 Exelixis Inc Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol
CA2923835C (fr) * 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Nouveaux amides anthraniliques et utilisation de ces derniers
EP3043822A1 (fr) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions pour prépaprer des cardiomyocytes
US20160340407A1 (en) 2014-01-14 2016-11-24 Dana-Farber Camcer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
EP3204516B1 (fr) 2014-10-06 2023-04-26 Dana-Farber Cancer Institute, Inc. Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
JP7046968B2 (ja) * 2017-03-02 2022-04-04 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ ２－（置換フェニルヘテロ）芳香族カルボン酸系ｆｔｏ阻害剤、その製造方法およびその使用
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) * 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
US2502451A (en) * 1945-05-07 1950-04-04 Ward Blenkinsop & Co Ltd Amino-alkyl esters of diphenylamine 2-monocarboxylic acids
US2553914A (en) * 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
DE2155106A1 (de) * 1970-11-06 1972-05-10 Ciba-Geigy Ag, Basel (Schweiz) Neue Nitrodiphenylamine, deren Herstellung und Verwendung
US3781358A (en) * 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
EP0242559A2 (fr) * 1986-03-15 1987-10-28 Hoechst Aktiengesellschaft Utilisation des acides benzoiques amino substitués comme remèdes pour la diarrhée et médicaments sur la base de ces composés
EP0316630A1 (fr) * 1987-10-27 1989-05-24 Warner-Lambert Company Dérivés hydroxamiques de l'acide fénamique ayant une activité inhibitrice de cyclooxygénase et 5-lipoxygénase
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
WO1999021840A1 (fr) * 1997-10-28 1999-05-06 Warner-Lambert Company Nouvelles quinazolin-2,4-diones substituees en 7, des plus utiles en tant qu'agents antibacteriens

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) * 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
US2502451A (en) * 1945-05-07 1950-04-04 Ward Blenkinsop & Co Ltd Amino-alkyl esters of diphenylamine 2-monocarboxylic acids
US2553914A (en) * 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
US3781358A (en) * 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
DE2155106A1 (de) * 1970-11-06 1972-05-10 Ciba-Geigy Ag, Basel (Schweiz) Neue Nitrodiphenylamine, deren Herstellung und Verwendung
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
EP0242559A2 (fr) * 1986-03-15 1987-10-28 Hoechst Aktiengesellschaft Utilisation des acides benzoiques amino substitués comme remèdes pour la diarrhée et médicaments sur la base de ces composés
EP0316630A1 (fr) * 1987-10-27 1989-05-24 Warner-Lambert Company Dérivés hydroxamiques de l'acide fénamique ayant une activité inhibitrice de cyclooxygénase et 5-lipoxygénase
WO1998037881A1 (fr) * 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
WO1999021840A1 (fr) * 1997-10-28 1999-05-06 Warner-Lambert Company Nouvelles quinazolin-2,4-diones substituees en 7, des plus utiles en tant qu'agents antibacteriens

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
A.H. COOK ET AL, J. CHEM. SOC., 1943, pages 417 - 419 *
CHEMICAL ABSTRACTS, vol. 35, no. 22, 20 November 1941, Columbus, Ohio, US; abstract no. 7965h, XP002142607 *
CHEMICAL ABSTRACTS, vol. 38, no. 1, 10 January 1944, Columbus, Ohio, US; abstract no. 105, XP002142608 *
CHEMICAL ABSTRACTS, vol. 59, no. 8, 14 October 1963, Columbus, Ohio, US; abstract no. 8753f, XP002142606 *
CHEMICAL ABSTRACTS, vol. 70, no. 3, 20 January 1969, Columbus, Ohio, US; abstract no. 11330, XP002142605 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142609 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142610 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142611 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142612 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142614 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142615 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142616 *
DATABASE CROSSFIRE BEILSTEIN INSTITUT FUER LITERATUR DER ORGANISCHEN CHEMIE; XP002142613 *
E.S. ENDELMAN ET AL, KHIM.-FARM. ZH., vol. 7, no. 12, 1973, pages 15 - 19 *
F. HUNZIKER ET AL, ARZNEIMITTEL-FORSCH., vol. 13, 1963, pages 324 - 328 *
M. TAKEDA ET AL, YAKUGAKU ZASSHI, vol. 89, no. 2, 1969, pages 158 - 163 *
N.A. MOKHORT, FARMAKOL. TOKSIKOL. (KIEV), no. 6, 1971, pages 108 - 111 *
V.O. YU ET AL, J. GEN. CHEM. USSR, vol. 11, 1941, pages 243 - 253 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7271178B2 (en) 2003-09-03 2007-09-18 Array Biopharma, Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7511058B2 (en) 2003-09-03 2009-03-31 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US9290468B2 (en) 2012-01-17 2016-03-22 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof
US9937158B2 (en) 2012-01-17 2018-04-10 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof

Also Published As

Publication number Publication date
BR9916857A (pt) 2001-12-04
EP1150950A2 (fr) 2001-11-07
CA2349180A1 (fr) 2000-07-20
WO2000041505A2 (fr) 2000-07-20
JP2002534446A (ja) 2002-10-15
AU2483400A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
WO2000041505A3 (fr) 4'heteroaryle diarylamines
BG103417A (en) Condensed pyrimidine bicyclic derivatives
WO1999054326A8 (fr) Dihydropyrimidines
GR3030342T3 (en) Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase.
PL346797A1 (en) Arylsulfonanilide ureas
WO1998051294A3 (fr) Procede et composition de traitement anti-cancer
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
EP0939627A4 (fr) Sulfamides de pentafluorobenzene et analogues
IL156967A0 (en) Camptothecin derivatives
DE69907419D1 (en) Antitumorwirkstoffe
WO2004084812A3 (fr) Analogues de « tamandarin », fragments associes et leurs methodes d'elaboration et d'utilisation
DE60214359D1 (en) Stickstoffbasierte camptothecin-derivate
CA2429133A1 (fr) Nouveaux derives imidazole, procede de production correspondant et utilisation de ces derives
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
CA2266759A1 (fr) Derives 3-mercaptoacetylamino-1,5-substitue-2-oxo-azepane, utilises comme inhibiteurs de metalloproteinase matrice
AU2003300385A1 (en) Anticancer compounds
AU5705099A (en) Compounds useful as aicarft inhibitors
MY104829A (en) 3-phenyl-5, 6-dihydrobenz [c]acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents.
DE69911017D1 (en) Arylsulfonanilid-phosphate
WO2003080624A3 (fr) Nouveaux dithiolopyrrolones ayant une action therapeutique
WO1996025400A3 (fr) Bisnaphtalimides substitues 3-aromatiques et 3-heteroaromatiques
AU3412600A (en) Peroxovanadium compounds as antineoplastic agents for the treatment of cancer
ZA994817B (en) 8H-thieno-[2,3-b]pyrrolizin-8-one compounds, a process for their preparation and pharmaceutical compositions containing them.
AU2002359762A1 (en) Luminacin analogs and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2349180

Country of ref document: CA

Ref country code: CA

Ref document number: 2349180

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004851

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999968160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889106

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593128

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999968160

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999968160

Country of ref document: EP